We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effectiveness of Intravitreal Avastin Injection for CRVO

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2012 by Ziv Hospital.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01678248
First Posted: September 3, 2012
Last Update Posted: September 3, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Ziv Hospital
  Purpose
to determine the effectivness of intravitreal avastin injection on visual acuity on people that suffer from central retinal vein occlusion

Condition
Central Retinal Vein Occlusion

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: The Effectiveness of Intravitreal Avastin Injection for CRVO

Further study details as provided by Ziv Hospital:

Estimated Enrollment: 68
Study Start Date: January 2006
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
patients who suffer from CRVO and were injected by bevazicumab intravitrealy
Criteria

Inclusion Criteria:

  • patients above 18 years old
  • suffer from CRVO
  • maximal visual acuity 6/15

Exclusion Criteria:

  • VA of LP
  • retinal disease other than CRVO
  • incomplete medical record
  • follow up less than 6 months
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01678248


Contacts
Contact: Joseph pikkel, M.D 972508434206 pikel.y@ziv.health.gov.il
Contact: Otzem Chassid, M.D 972506266059 otzem.c@ziv.health.gov.il

Locations
Israel
Ziv Medical Center Recruiting
Safed, Israel, 13100
Contact: Otzem Chassid, M.D       otzem.c@ziv.health.gov.il   
Principal Investigator: Joseph Pikkel, M.D         
Sponsors and Collaborators
Ziv Hospital
  More Information

Responsible Party: Ziv Hospital
ClinicalTrials.gov Identifier: NCT01678248     History of Changes
Other Study ID Numbers: 0048-12-ZIV
First Submitted: August 29, 2012
First Posted: September 3, 2012
Last Update Posted: September 3, 2012
Last Verified: August 2012

Additional relevant MeSH terms:
Retinal Vein Occlusion
Retinal Diseases
Eye Diseases
Venous Thrombosis
Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents